<a href="https://www.fiercebiotech.com/biotech/autobahn-races-toward-pivotal-trial-after-thyroid-hormone-mimic-eases-bipolar-depression-ph" hreflang="en">Autobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2</a>
Autobahn Therapeutics is advancing towards a pivotal trial for elunetirom, a thyroid hormone mimic that significantly reduced depression severity in patients with bipolar disorder during a phase 2 trial, achieving a 75% response rate and 50% remission rate. The company plans to initiate a phase 3 trial by mid-2027, aiming to bring this promising treatment to market while minimizing side effects associated with traditional thyroid hormone therapies.
Autobahn Therapeutics' elunetirom, a thyroid hormone receptor stimulator targeting the brain, has shown promising results in a phase 2 trial for bipolar depression by significantly improving depression severity and daily life function, with a strong safety profile. Given the successful phase 2 outcomes and FDA fast track designation, this positions elunetirom as a potentially impactful treatment moving towards a pivotal phase 3 trial, making it a noteworthy candidate for investment and partnership opportunities in CNS-directed therapies.